Study Medication Participants will be randomized for a 12 week treatment with two different active study agents. Consequently, independent of treatment allocation, beneficial effects can be expected, as both SGLT-2 inhibitors and SU derivatives improve glycemic control. Both study medications have been approved for blood-glucose lowering treatment in T2DM patients and, based on currently available data, are considered to be safe. Furthermore, SGLT-2 inhibitors in general may decrease blood pressure and body weight compared to gliclazide.